Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

Delayed Quote. Delayed  - 05/26 10:02:02 pm
223.12 USD   -0.55%
05/16 CARL ICAHN : Icahn takes new 19.8 million share stake in Conduent in..
05/16 ALLERGAN PLC : ex-dividend day
05/13 High-profile Snap stakeholders revealed in filings
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
05/22/2017 05/23/2017 05/24/2017 05/25/2017 05/26/2017 Date
219.52(c) 220.66(c) 224.16(c) 224.36(c) 223.12 Last
1 770 195 1 667 221 2 805 211 1 421 280 1 695 589 Volume
+0.18% +0.52% +1.59% +0.09% -0.55% Change
More quotes
Financials ($)
Sales 2017 15 821 M
EBIT 2017 7 624 M
Net income 2017 -1 759 M
Debt 2017 17 074 M
Yield 2017 1,29%
Sales 2018 16 934 M
EBIT 2018 8 303 M
Net income 2018 -670 M
Debt 2018 16 454 M
Yield 2018 1,33%
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 5,84x
EV / Sales2018 5,42x
Capitalization 75 355 M
More Financials
Company
Allergan Plc engages in the research, development, and manufacture of pharmaceutical products.It operates through the following segments: US Specialized Therapeutics; US General Medicine, and International.The US Specialized Therapeutics segment includes sales and expenses relating to branded... 
Sector
Pharmaceuticals
Calendar
05/31 | 03:00pmPresentation
More about the company
Surperformance© ratings of Allergan plc
Trading Rating : Investor Rating :
More Ratings
Latest news on ALLERGAN PLC
05/16 CARL ICAHN : Icahn takes new 19.8 million share stake in Conduent in first quart..
05/16 ALLERGAN PLC : ex-dividend day
05/13 High-profile Snap stakeholders revealed in filings
05/13 High-profile Snap stakeholders revealed in filings
05/09DJALLERGAN : Thin Is In as Allergan Dodges Generics Bullet -- Heard on the Street
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/03DJPerrigo Says Investigators Searched Its Offices in Generic-Drug Probe
02/24 ALLERGAN PLC : ex-dividend day
02/21 Collapse of Kraft-Unilever tie-up extends run of failed mega-deals
02/13 Allergan to buy fat-fighter Zeltiq Aesthetics for $2.48 billion
More news
Sector news : Pharmaceuticals - NEC
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
05/23DJALEXION PHARMACEUTICALS : Shakeup Continues as Four Executives Exit -- 2nd Updat..
More sector news : Pharmaceuticals - NEC
Latest Tweets
05/25Insider Selling: Allergan plc $AGN Director Sells $416,430.05 in Stock  
05/2514 Stocks For 2017 And Beyond - May Update  
05/25Allergan plc's outperform rating reiterated at Sanford C. Bernstein.  
05/25Allergan plc $AGN Given Outperform Rating at Sanford C. Bernstein  
05/25Allergan Announces Pricing of Tender Offers by Certain Subsidiaries  
More tweets
Qtime:157
News from SeekingAlpha
05/25 14 Stocks For 2017 And Beyond - May Update
05/24 ALLERGAN'S DEBT REFINANCING : When More Is Less
05/24 Tracking Wallace Weitz's Weitz Investment Management Portfolio - Q1 2017 Upda..
05/23 Allergan launches offering of senior unsecured notes to rollover existing deb..
05/23 Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2017 Update
Advertisement
Chart ALLERGAN PLC
Duration : Period :
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Full-screen chart
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 273 $
Spread / Average Target 22%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Robert A. Stewart Chief Operating Officer
Maria Teresa Hilado Chief Financial Officer
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC5.07%75 355
JOHNSON & JOHNSON10.68%343 545
ROCHE HOLDING LTD.14.88%236 038
NOVARTIS AG6.68%212 104
PFIZER INC.-1.32%191 517
MERCK & CO., INC.10.48%177 895
More Results